Fosfomycin Antimicrobial Combination for Bovine Mastitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bovine mastitis are often costly, time-consuming, and not fully efficacious, leading to significant economic losses in the dairy industry due to prolonged milk withdrawal, reduced dairy product quality, and increased veterinary costs.
Innovation Solution
A pharmaceutical composition combining fosfomycin, a phosphonic acid, with antimicrobials such as enrofloxacin, cefazolin, or pirlimycin is administered intra-mammarily to prevent or treat mastitis, enhancing antibiotic efficacy by inhibiting the differentiation of persisting bacterial variants and blocking clonal expansion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fosfomycin is used alone to treat mastitis, then bacterial population is reduced, but persisting variants differentiate and undergo clonal expansion leading to treatment failure
Solution Approach 1:
The patent combines fosfomycin with another antimicrobial agent to create a synergistic effect. Fosfomycin reduces the bacterial population while the second agent prevents the differentiation and clonal expansion of persisting variants, thereby resolving the contradiction between initial bacterial reduction and prevention of treatment failure.
Solution Approach 2:
The combination therapy performs preliminary action by eliminating susceptible bacteria with fosfomycin before the persisting variants can differentiate and expand clonally. This preliminary reduction prevents the subsequent harmful expansion phase.
2Reliability
If multiple successive intramammary applications of antibiotics are used, then treatment coverage is improved, but treatment duration and cost increase
Solution Approach 1:
By merging two antimicrobial agents with different mechanisms of action into a single formulation, the patent achieves broader coverage in one application rather than requiring multiple successive applications of single agents, thereby reducing treatment duration while maintaining or improving efficacy.
Solution Approach 2:
The patent changes the parameter of drug concentration and combination by using clinically achievable concentrations of two agents together, achieving enhanced efficacy without requiring excessive dosing or prolonged treatment periods.
3Reliability
If higher drug concentrations are used to achieve better efficacy, then bacterial elimination is improved, but clinically achievable concentrations are exceeded
Solution Approach 1:
The patent merges two antimicrobial agents that each work at clinically achievable concentrations, where their combined effect achieves superior bacterial elimination without requiring either agent to be used at toxic or non-compliant high concentrations.
Solution Approach 2:
The patent optimizes the parameter of drug concentration by using moderate, clinically achievable levels of two agents in combination, rather than attempting to achieve high-level elimination with a single agent at excessively high concentrations.
Data Source
AI summary
The present invention relates to a pharmaceutical composition and methods of treating and/or preventing mastitis in non-human mammals. More particularly, the present invention relates to the treatment of mastitis in cows. The pharmaceutical composition comprises a mixture of a phosphonic acid and at least one antimicrobial.